|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1995-01-01 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期1962-05-01 |
靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
|
最高研发阶段撤市 |
|
首次获批日期1958-06-25 |
A 12-Month Noninterventional, Postmarketing, Multicenter Study to Evaluate the Effectiveness of Briviact® (Brivaracetam) as Adjunctive Therapy in Patients With Epilepsy With Partial-onset Seizures in Daily Clinical Practice
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard clinical practice.
100 项与 Pharm Research Associates (UK) Ltd. 相关的临床结果
0 项与 Pharm Research Associates (UK) Ltd. 相关的专利(医药)
100 项与 Pharm Research Associates (UK) Ltd. 相关的药物交易
100 项与 Pharm Research Associates (UK) Ltd. 相关的转化医学